Welcome to our dedicated page for Omada Health SEC filings (Ticker: OMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omada Health, Inc. (Nasdaq: OMDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a virtual-first, between-visit healthcare provider focused on cardiometabolic and musculoskeletal conditions, Omada uses these filings to report on its financial condition, operations, and material events related to its digital chronic care platform.
Investors can review current reports on Form 8-K, which Omada uses to furnish press releases announcing quarterly results and other significant developments. For example, recent 8-K filings reference earnings press releases for periods in which the company reported revenue, member growth, and updates on its GLP-1-related offerings and AI capabilities. These current reports help readers connect headline financial and operational metrics to the underlying SEC record.
In addition to 8-Ks, Omada’s periodic reports on Form 10-Q and Form 10-K (accessible through the SEC and linked from this page when available) typically contain more detailed information on revenue composition, cost structure, research and development spending, and risks associated with its virtual care and GLP-1 programs. These filings are particularly relevant for understanding how Omada’s cardiometabolic and musculoskeletal programs, GLP-1 Care Tracks, and prescribing and medication management capabilities are reflected in its financial statements and risk disclosures.
Stock Titan enhances this information with AI-powered summaries that explain key points from lengthy filings, helping readers quickly identify sections related to Omada’s chronic care model, GLP-1 initiatives, and digital health operations. Users can also monitor updates to OMDA’s filings in near real time, including new 8-Ks, 10-Qs, 10-Ks, and other relevant forms, to follow how the company reports on its performance and material events over time.
Omada Health (OMDA) reported Q3 2025 results showing strong top-line growth and improved losses. Revenue for the three months ended September 30, 2025 rose to $68.0 million from $45.5 million a year ago, driven by services revenue of $62.9 million and hardware revenue of $5.1 million. Gross profit increased to $45.1 million from $28.6 million.
Operating loss narrowed to $2.5 million from $8.5 million, and net loss improved to $3.2 million from $9.2 million. Basic and diluted net loss per share was $(0.06) (vs. $(1.18)), reflecting a larger post‑IPO share count.
Liquidity strengthened materially. Cash and cash equivalents were $198.6 million at quarter‑end (vs. $76.4 million at December 31, 2024). The company completed an IPO on June 9, 2025, generating $151.6 million in net proceeds and subsequently repaid its MidCap term loan and revolver, recording a $2.1 million loss on debt extinguishment. Accounts receivable increased to $41.4 million, with significant contributions from affiliates of The Cigna Group. Shares outstanding were 57,908,047 as of November 5, 2025.
Omada Health, Inc. (OMDA) reported that it issued a press release announcing financial results for the three months ended September 30, 2025. The press release is furnished as Exhibit 99.1 to a Form 8-K under Item 2.02 and, as stated, is furnished and not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference except as specifically referenced.
Jonathan D. Root, a director of Omada Health, Inc. (OMDA), reported the receipt of 657 restricted stock units (RSUs) on 10/05/2025 issued under the company's Non-Employee Director Compensation Program in lieu of retainer fees. Following this grant, Mr. Root directly beneficially owns 10,630 shares and indirectly beneficially owns 4,717, (4,571,769 + 146,257) shares through affiliated USVP X funds, where he is a managing member of the general partner and disclaims direct beneficial ownership except for any pecuniary interest. The Form 4 was signed by an attorney-in-fact on 10/07/2025.
Insider transaction summary: A Form 4 shows that Trevor Fetter, a director of Omada Health, Inc. (OMDA), was granted 712 restricted stock units (RSUs) on 10/05/2025 as payment under the non-employee director compensation program in lieu of retainer fees. Each RSU converts to one share at settlement and the grant carried a reported price of $0 (i.e., issued as compensation). After the grant, the filing reports Mr. Fetter directly beneficially owns 10,705 shares and indirectly beneficially owns 111,200 shares through an LLC he solely controls, for a combined beneficial position of 121,905 shares.
The form was signed by an attorney-in-fact on 10/07/2025. The filing discloses that settlement timing follows plan terms and that the indirect holdings are held via the limited liability company of which Mr. Fetter is the sole member.
Insider transaction by Omada Health director Jeryl L. Hilleman: the filing reports that on 10/05/2025 the reporting person was granted 1,126 restricted stock units (RSUs) under the company’s Non-Employee Director Compensation Program in lieu of cash retainer fees. Each RSU represents the right to receive one share of common stock with settlement terms set by the Program. After the grant, the reporting person beneficially owns 11,238 shares of common stock. The RSUs were recorded at a price of $0 because they were compensation awards rather than purchases. The Form 4 was signed by an attorney-in-fact on 10/07/2025.
Steven L. Cook, Chief Financial Officer of Omada Health, Inc. (OMDA), reported a sale of shares on 09/05/2025. The Form 4 shows a disposition of 2,006 shares of common stock at a price of $24.28 per share, leaving Mr. Cook with 63,783 shares owned directly after the transaction. The filing was signed by an attorney-in-fact on 09/09/2025.
Sean P. Duffy, Omada Health insider sale disclosed. The filing shows that on 09/05/2025 Mr. Duffy, who serves as Chief Executive Officer and a Director, disposed of 4,413 shares of Omada Health common stock at a price of $24.28 per share. After the sale his reported direct beneficial ownership is 140,323 shares. The filing also reports 861,109 shares held indirectly in family trusts for the benefit of his family, which he disclaims beneficial ownership of except to the extent of any pecuniary interest. The Form 4 was signed by an attorney-in-fact on 09/09/2025.
Omada Health insider sale: The Form 4 shows Wei-Li Shao, President and officer of Omada Health, sold 2,407 shares of common stock on 09/05/2025 at a price of $24.28 per share. After the sale, Shao beneficially owned 76,540 shares, reported as direct ownership. The filing was signed by an attorney-in-fact on 09/09/2025.
Omada Health, Inc. Schedule 13G shows that a set of related reporting persons (U.S. Venture Partners X, L.P.; USVP X Affiliates, L.P.; Presidio Management Group X, L.L.C.; and Casey M. Tansey) report collective beneficial ownership of the company's common stock. The filings report 4,571,769 shares held directly by USVP X and an additional 146,257 shares held by USVP X Affiliates, for a combined reported position of 4,718,026 shares. The filing states this represents approximately 8.2% of the outstanding common stock based on 57,574,921 shares of common stock outstanding used for the calculation. The reporting persons disclaim group status and clarify that Presidio Management Group X, L.L.C. acts as general partner and certain named individuals may be deemed to share voting and dispositive power, while each disclaims beneficial ownership except to the extent of any pecuniary interest.
The filing is a Schedule 13G disclosing that Andreessen Horowitz-related entities and principals report beneficial ownership in Omada Health, Inc. (OMDA) as of June 30, 2025. Andreessen Horowitz Fund IV, L.P. directly holds 4,210,602 shares (reported as 7.6% of the class) and AH Parallel Fund IV, L.P. directly holds 403,972 shares (reported as 0.7% of the class), producing an aggregate reported position of 4,614,574 shares, equal to 8.3% of outstanding common stock based on 55,744,340 shares outstanding per the issuer prospectus dated June 5, 2025. The filing identifies Andreessen and Horowitz as individuals with shared voting and dispositive power over the aggregated holdings and includes powers of attorney and a joint filing agreement.